Drug profile · INN
tigecycline
TIGECYCLINE ACCORD
tigecycline (TIGECYCLINE ACCORD) is a bacterial 70s ribosome inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — tigecycline
- US status
- approved
- Class
- Antiinfectives for systemic use (J01)
- Route
- INTRAVENOUS
- Patents
- 4
- Programs
- 5
- Data quality
- 0.89
Quick answer
tigecycline (TIGECYCLINE ACCORD) is a bacterial 70s ribosome inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial 70S ribosome inhibitor
Primary target: Bacterial 70S ribosome
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 8207361
Tigecycline crystalline forms and processes for preparation thereof
granted -
US 8198469
Crystalline forms of tigecycline and processes for preparation thereof
granted -
US 8198470
Crystalline form II of tigecycline and processes for preparation thereof
granted -
US 7871993
Tigecycline crystalline forms and processes for preparation thereof
granted
Frequently asked questions
What is tigecycline?
tigecycline (TIGECYCLINE ACCORD) is a bacterial 70s ribosome inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for tigecycline?
TIGECYCLINE ACCORD is a marketed brand name for tigecycline. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tigecycline?
tigecycline has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.